Publication Name	World Journal of Clinical Cases
Manuscript ID	80040
Country	India

Received	2022-09-14 18:48
Peer-Review Started	2022-09-14 18:51
To Make the First Decision
Return for Revision	2022-10-13 01:25
Revised	2022-10-30 06:31
Second Decision	2022-12-01 03:15
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-12-05 07:42
Articles in Press	2022-12-05 07:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-12-12 04:35
Publish the Manuscript Online	2022-12-26 18:23

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Rheumatology
Manuscript Type	Letter to the Editor
Article Title	Precautions before starting tofacitinib in persons with rheumatoid arthritis
Manuscript Source	Unsolicited Manuscript
All Author List	Raktim Swarnakar and Shiv Lal Yadav
ORCID	Author(s) ORCID Number Raktim Swarnakar http://orcid.org/0000-0002-7221-2825
Funding Agency and Grant Number
Corresponding Author	Raktim Swarnakar, MBBS, MD, Doctor, Doctor, Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi , New Delhi 11049, Delhi, India. raktimswarnakar@hotmail.com
Key Words	Tofacitinib; Rheumatoid arthritis; DMARDs; Disease-modifying; Precaution; Side-effects
Core Tip	Tofacitinib is a disease-modifying drug in rheumatoid arthritis. It has many side effects, especially in susceptible people. Before starting tofacitinib we must take precautions regarding cardiovascular status, infections and malignancy.
Publish Date	2022-12-26 18:23
Citation	Swarnakar R, Yadav SL. Precautions before starting Tofacitinib in persons with Rheumatoid Arthritis. World J Clin Cases 2022; 10(36): 13467-13469
URL	https://www.wjgnet.com/2307-8960/full/v10/i36/13467.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i36.13467

Full Article (PDF)	WJCC-10-13467.pdf
Full Article (Word)	WJCC-10-13467.docx
Manuscript File	80040_Auto_Edited-YXX-JLW.docx
Answering Reviewers	80040-Answering reviewers.pdf
Audio Core Tip	80040-Audio core tip.aac
Conflict-of-Interest Disclosure Form	80040-Conflict-of-interest statement.pdf
Copyright License Agreement	80040-Copyright license agreement.pdf
Peer-review Report	80040-Peer-review(s).pdf
Scientific Misconduct Check	80040-Bing Xing YX-2.png
Scientific Editor Work List	80040-Scientific editor work list.pdf
CrossCheck Report	80040-CrossCheck report.pdf